Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19

Официальное название

Exploring Creatine Supplementation for Improved Exercise Capacity and Reduced Fatigue in Long COVID-19: A Randomized Controlled Trial

Обзор

Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM

Подробное описание

cognitive dysfunction, and post-exertional malaise are common complaints of those living with Post-COVID Condition (PCC), a sequelae of symptoms that persist beyond acute infection. Similar to other types of post-viral fatigue, the diagnosis and treatment of PCC are challenging due to the lack of a valid biomarker for the condition. Though the etiology of PCC is not well understood, recent research has found reduced skeletal muscle creatine concentration in those with PCC, which may contribute to fatigue. The objective of this study is to determine if eight weeks of creatine monohydrate supplementation (8g/day) improves symptoms of fatigue, cognition, exercise capacity, and PEM in individuals living with PCC.

Participants will complete two cardiopulmonary exercise tests 24-hours apart on a cycle ergometer before and after an eight-week intervention period. Venous blood samples will be collected before and after exercise on both days to assess changes in mitochondrial function. During the intervention, participants will be randomly assigned to supplement with 8g/day of either creatine monohydrate or a control (maltodextrin). Cognition will be indirectly assessed via self-report of cognitive symptom frequency and severity at baseline, mid-intervention (i.e., 4 weeks) and post-intervention.

Вмешательства

• Пищевая добавка Creatine monohydrate
  8 g/day creatine monohydrate powder

Первичные конечные точки

• Oxygen consumption at ventilatory threshold [Срок оценки: From enrollment to the end of intervention at 8 weeks]
• Heart rate at ventilatory threshold [Срок оценки: From enrollment to the end of intervention at 8 weeks]

Вторичные конечные точки (2)

• Fatigue [Срок оценки: From baseline to mid intervention (4 weeks) to the end of the intervention (8 weeks)]
• Brain fog [Срок оценки: From baseline to mid intervention (4 weeks) to post intervention (8 weeks)]

Критерии участия

Критерии включения

• Experiencing symptoms at least 3 months after a COVID-19 diagnosis confirmed by positive polymerase chain reaction (PCR) test
• Experiencing post-exertional malaise, as per the DePaul Symptom Questionnaire

Критерии исключения

• Allergy or intolerance to creatine monohydrate or maltodextrin
• Supplemented with creatine in the past eight weeks
• orthopaedic injury or condition that would prevent exercise testing
• change in medication related to Long COVID symptom management in the past month.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Поддерживающая терапия

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06992414 · REB25-0930

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗